La cadena de opciones muestra datos clave de las opciones de acciones de CVC Capital Partners a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para CVC Capital Partners..

CVC Capital Partners (OTC:CVCCF) Bolsa, Cadena de Opciones

Citibank established CVC Capital Partners in 1981 as its European venture capital business. Spun out as a wholly independent entity in 1993, CVC, in due course, transformed into a manager of private equity, private credit, real estate, and infrastructure funds. CVC invests most of its funds in Europe and the United States, with a smaller exposure to Asia.

CVC CAPITAL PARTNERS PLC by CVC CAPITAL PARTNERS PLC

CVC Capital Partners PLC

On Wednesday,&nbsp;Biogen Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>)&nbsp;reported third-quarter adjusted EPS of $4.08, down 6%, beating&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">the consensus of $3.79</a>.
The company&nbsp;<a target="_blank" href="https://investors.biogen.com/static-files/75f1044b-a254-48e9-acdb-bcb0263930b0" rel="noreferrer noopener">reported</a> sales of&nbsp;$2.47 billion, down 3% year over on constant currency and reported basis, beating the consensus of $2.43 billion.
Multiple sclerosis revenue of $1.05 billion decreased by 9% (down 9% on constant currency). The multiple sclerosis drug Tysabri sales were down to $406.1 million from $456.3 million.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/41049022/biogen-terminates-collaboration-with-sage-therapeutics-for-neurological-disorder-candidate" rel="noreferrer noopener">Biogen Terminates Collaboration With Sage Therapeutics For Neurological Disorder Candidate</a>
Rare disease revenue&nbsp;increased&nbsp;10% year over year (up 10% CC) to $495 million.
Spinraza&#8217;s revenue fell to $381.4 million from $448.2 million a year ago.
Revenues from Skyclarys, acquired via Reata acquisition, reached $102.3 million during the quarter.
In Alzheimer&#8217;s disease, Biogen said Leqembi third quarter global in-market sales of approximately $67 million, including U.S. in-market sales of approximately $39 million; E.U. CHMP re-examination expected to be completed this year.
Postpartum depression drug Zurzuvae&#8217;s third-quarter sales reached $22 million.
Guidance: Biogen raised its 2024 adjusted EPS guidance to $16.10-$16.60&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40105919/biogen-q2-earnings-beats-consensus-lifts-2024-profit-forecast-as-new-drug-launches-expected-to-of" rel="noreferrer noopener">versus prior guidance</a> of $15.75-$16.25 and consensus of $16.19.
Biogen continues to expect 2024 revenue to decline by a low-single-digit percentage, with core pharmaceutical revenue to be relatively flat compared to 2023, as further declines in multiple sclerosis product revenues are expected to be offset by increases in revenue from new product launches.
For 2024 compared to 2023, Biogen expects operating income to grow at a high-teen percentage with mid-single digit percentage point operating margin improvement.
Price Action: BIIB stock is down 1.37% at $180.95&nbsp;at the last check on Wednesday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/10/41624198/gsks-q3-earnings-hit-by-lower-than-expected-vaccine-sales-cautions-lower-revenue-for-2024" target="_blank" rel="noreferrer noopener">GSK&#8217;s Q3 Earnings Hit By Lower Than Expected Vaccine Sales, Cautions Lower Revenue For 2024</a></li>
</ul>

Biotech

Earnings

News

Guidance

Health Care

General

BIIB

Biogen's Q3 Profit Beats Expectations On Lower Multiple Sclerosis Revenues But New Products Offset Losses, Raises Profit Outlook

Evercore ISI Group analyst Mark Lipacis maintains Advanced Micro Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) with a Outperform and raises the price target from $193 to $198.

Price Target

Analyst Ratings

Evercore ISI Group Maintains Outperform on Advanced Micro Devices, Raises Price Target to $198

Benchmark analyst Bill Sutherland reiterates Huron Consulting Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HURN#NASDAQ">HURN</a>) with a Buy and maintains $140 price target.

Reiteration

HURN

Benchmark Reiterates Buy on Huron Consulting Gr, Maintains $140 Price Target

UBS analyst Thomas Wadewitz maintains Heartland Express (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTLD#NASDAQ">HTLD</a>) with a Neutral and lowers the price target from $13 to $12.

HTLD

UBS Maintains Neutral on Heartland Express, Lowers Price Target to $12

UBS analyst John Lovallo maintains D.R. Horton (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHI#NYSE">DHI</a>) with a Buy and lowers the price target from $217 to $214.

UBS Maintains Buy on D.R. Horton, Lowers Price Target to $214

UBS analyst Jay Sole maintains Crocs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CROX#NASDAQ">CROX</a>) with a Neutral and lowers the price target from $146 to $122.

CROX

UBS Maintains Neutral on Crocs, Lowers Price Target to $122

On Wednesday,&nbsp;AbbVie Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) reported third-quarter adjusted EPS of $3.00, up from $2.95 a year ago, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $2.92</a>.
Net revenues reached $14.46 billion, up 3.8%, beating the&nbsp;consensus of $14.28 billion. Sales were up&nbsp;4.9% <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/n41621806/abbvie-reports-third-quarter-2024-financial-results" rel="noreferrer noopener">on an operational basis</a>.
The immunology portfolio generated&nbsp;$7.05 billion&nbsp;in sales, up 3.9% on a reported basis or 4.8% on an operational basis.
<ul>
<li>Humira revenues were $2.23 billion (down 37.2%), Skyrizi sales reached $3.21 billion (up 50.8%), and Rinvoq revenues were $1.61 billion (up 45.3%).&nbsp;</li>
</ul>
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41384990/fda-approves-abbvies-parkinsons-treatment-medicare-coverage-expected-next-year" rel="noreferrer noopener">FDA Approves AbbVie&#8217;s Parkinson&#8217;s Treatment, Medicare Coverage Expected Next Year</a>
Oncology product sales were&nbsp;$1.69 billion, up 11.6% or 13.0% on an operational basis.
<ul>
<li>Imbruvica revenues were $828 million (down 8.8%), Venclexta sales increased 14.8% to $677 million, and Elahere's net revenues were&nbsp;$139 million.</li>
</ul>
Neuroscience revenues reached $2.36 billion, up 15.6% on a reported basis or 16.0% on an operational basis.
<ul>
<li>Botox Therapeutic sales were&nbsp;$848 million, up 13.4%. Aesthetics portfolio sales reached $1.24 billion, down 0.1%. Global Botox Cosmetic revenues were&nbsp;$671 million, up 8.2%.</li>
</ul>
Dividend: AbbVie also increased its quarterly cash dividend from $1.55 per share to $1.64 per share, beginning with the dividend payable on Feb. 14, 2025, to shareholders of record as of Jan. 15, 2025.
Monday, AbbVie&nbsp;agreed to acquire Aliada Therapeutics for $1.4 billion&nbsp;in cash.
Aliada is a biotechnology company advancing therapies using a novel blood-brain barrier-crossing technology for the treatment of central nervous system diseases. Aliada&#8217;s lead investigational asset utilizing this delivery technology, ALIA-1758, is in development <a href="https://www.benzinga.com/pressreleases/24/10/n41571181/abbvie-to-acquire-aliada-therapeutics-strengthening-focus-in-alzheimers-disease-and-neuroscience-p" target="_blank" rel="noreferrer noopener">for Alzheimer&#8217;s disease</a>.
Guidance: AbbVie raised its 2024 adjusted EPS guidance to $10.90-$10.94 from <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/07/39992204/abbvie-wins-analyst-confidence-with-q2-beat-diverse-portfolio-fuels-long-term-growt" target="_blank" rel="noreferrer noopener">prior guidance of $10.67-$10.87</a> compared to consensus of $10.85, which includes an unfavorable impact of 64 cents per share related to acquired IPR&amp;D and milestones expense incurred year-to-date through the third quarter 2024.
In a conference call, AbbVie said it expects Skyrizi sales of $11.5 billion and Rinvoq sales of $5.8 billion in 2024.
Price Action: ABBV stock is up 1.8% at $192.95 at last check on Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/10/41624533/caterpillar-q3-earnings-revenue-falls-short-of-expectations-ceo-anticipates-muted-china-demand" target="_blank" rel="noreferrer noopener">Caterpillar Q3 Earnings: Revenue Falls Short Of Expectations, CEO Anticipates Muted China Demand</a></li>
</ul>
Photo: Formatoriginal/Shutterstock.com

Large Cap

Dividends

Trading Ideas

ABBV

AbbVie Tops Q3 Expectations As Skyrizi, Rinvoq Drive Growth

UBS analyst Timothy Arcuri maintains Advanced Micro Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) with a Buy and lowers the price target from $210 to $205.

UBS Maintains Buy on Advanced Micro Devices, Lowers Price Target to $205

WIIM

SMMT

Summit Therapeutics shares are trading lower. The company reported Q3 financial results.

AT&T Launches Industry-First Single-Box Solution For Seamless Fiber And 5G Integration, Offering Reliable Connectivity With Automatic Failover For Business Networks

Benchmark analyst Kurt Hallead reiterates Precision Drilling (TSX:<a class="ticker" href="https://www.benzinga.com/stock/PD#TSX">PD</a>) with a Buy and maintains C$115 price target.

TSX:PD

Benchmark Reiterates Buy on Precision Drilling, Maintains C$115 Price Target

UBS analyst Damian Karas maintains Zebra Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZBRA#NASDAQ">ZBRA</a>) with a Buy and raises the price target from $390 to $445.

ZBRA

UBS Maintains Buy on Zebra Technologies, Raises Price Target to $445

Cheetah Net Supply Chain's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTNT#NYSE">CTNT</a>) short percent of float has risen 3681.69% since its last report. The company recently reported that it has 768 thousand shares sold short, which is 53.7% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.0 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Cheetah Net Supply Chain Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730297722_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Cheetah Net Supply Chain has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Cheetah Net Supply Chain's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Cheetah Net Supply Chain's peer group average for short interest as a percentage of float is 6.20%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

CTNT

How Is The Market Feeling About Cheetah Net Supply Chain?

Waste Management's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WM#NYSE">WM</a>) short percent of float has fallen 6.1% since its last report. The company recently reported that it has 3.09 million shares sold short, which is 0.77% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.75 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Waste Management Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730297718_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Waste Management has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Waste Management's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Waste Management's peer group average for short interest as a percentage of float is 3.46%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

How Is The Market Feeling About Waste Management?

Oshkosh's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OSK#NYSE">OSK</a>) short percent of float has fallen 3.41% since its last report. The company recently reported that it has 1.21 million shares sold short, which is 2.83% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.63 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Oshkosh Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730297712_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Oshkosh has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Oshkosh's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Oshkosh's peer group average for short interest as a percentage of float is 5.83%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Peering Into Oshkosh's Recent Short Interest

BMO Capital analyst Ameet Thakkar reiterates First Solar (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NASDAQ">FSLR</a>) with a Outperform and lowers the price target from $286 to $260.

FSLR

BMO Capital Reiterates Outperform on First Solar, Lowers Price Target to $260

UBS analyst Jon Windham maintains Waste Management (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WM#NYSE">WM</a>) with a Neutral and raises the price target from $220 to $226.

UBS Maintains Neutral on Waste Management, Raises Price Target to $226

<a href="https://www.benzinga.com/news/24/10/41608242/trump-media-technology-stock-soars-after-msg-rally-will-the-gains-hold">News regarding the upcoming election </a>has made shares of Trump Media &amp; Technology Group Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>) skyrocket. 
But as you can see on the chart, the stock has run into resistance at a price level that was resistance before. This is why our team of expert traders has made it our <a href="https://www.benzinga.com/topic/stock-of-the-day">Stock of the Day</a>.
This price action isn't a coincidence. Stocks hitting resistance and reversing off of levels that had been resistance previously is a common occurrence in the market. It happens because of investor and trader psychology.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="630" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/30100324/1-29-1024x630.png" alt="" class="wp-image-621862" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/30100324/1-29-1024x630.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/30100324/1-29-300x185.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/30100324/1-29-768x473.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/30100324/1-29.png 1186w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read Also: <a href="https://www.benzinga.com/news/24/10/41615605/kamala-harris-urges-change-at-ellipse-rally-time-to-turn-the-page-on-drama-and-conflict-slams-trump">Kamala Harris Urges Change At Ellipse Rally: &#8216;Time To Turn The Page On Drama And Conflict&#8217; — Slams Trump For Jan. 6 Riots</a>
Many stock market analysts believe that relevant news — in this case, an election — can make a stock move. To a degree they are correct. But short-term imbalances in supply and demand and investor psychology can also move stocks.
There are people who bought shares of Trump media around $53.50 in May. They came to think their decision to do so was a mistake when the price dropped soon after. Many of these remorseful buyers vow to sell their shares.
But they don't want to lose any money. So, they decided to be patient and wait for the stock to eventually return to their buying price. Now that that has happened, they place sell orders. This way they can exit their positions at breakeven.
This large concentration of sell orders has created resistance around the same price level that had been resistance in May.
Sometimes, shares reverse and sell off after they reach resistance levels. This is also due to psychology. It happens because of anxious sellers.
Some of the traders and investors who are trying to sell their stock around the resistance become concerned. They are worried that others will be willing to sell their shares at a lower price. These concerned sellers know that this is who the buyers will go to.
As a result, they reduce the prices that they are willing to sell their shares for. Other concerned sellers see this and also reduce the prices they are willing to sell their shares at. This action can result in a snowball effect that pushes the price lower.
Savvy traders understand that buyer's remorse can create resistance at prices that were previously resistance. They also know that anxious sellers can push prices lower by undercutting each other. These dynamics can create profitable trading opportunities.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/24/10/41623984/us-economy-grows-less-than-expected-in-q3-yet-private-employment-soars-by-233-000">US Economy Grows Less Than Expected In Q3, Yet Private Employment Soars By 233,000 In October</a></li>
</ul>
Image: Shutterstock

Technicals

Stock Of The Day: Trump Media & Technology Runs Into Resistance

BMO Capital analyst Keith Bachman reiterates Check Point Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHKP#NASDAQ">CHKP</a>) with a Market Perform and lowers the price target from $238 to $215.

CHKP

BMO Capital Reiterates Market Perform on Check Point Software, Lowers Price Target to $215

Martin Marietta Materials Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MLM#NYSE">MLM</a>) reported a&nbsp;third-quarter revenue decline of&nbsp;5% to&nbsp;$1.889 billion,&nbsp;missing the <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/g41620752/martin-marietta-reports-third-quarter-2024-results" rel="noreferrer noopener">consensus of&nbsp;$1.934 billion</a>.
Gross profit was&nbsp;$599 million (-11%), and the margin contracted to&nbsp;32%&nbsp;from&nbsp;34% a year ago.&nbsp;
Building Materials business revenue was&nbsp;$1.8 billion (-6%), and the corresponding gross profit was&nbsp;$588&nbsp;million (-9%).
Aggregate shipments decreased by&nbsp;3.9%&nbsp;to 53.7&nbsp;million tons, while the average selling price increased by&nbsp;7.7% (or&nbsp;8.9%&nbsp;on an organic mix-adjusted basis) to $21.52 per ton.
Adjusted EBITDA declined&nbsp;8% to&nbsp;$646 million in the quarter. EPS&nbsp;fell 15% to&nbsp;$5.91, <a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">missing the consensus of&nbsp;$6.32</a>.
Martin Marietta&#8217;s operating cash flow for the nine months stood at&nbsp;$773&nbsp;million, compared with&nbsp;$973&nbsp;million for the prior year.
The company held&nbsp;$52&nbsp;million of cash and cash equivalents and&nbsp;$1.1 billion of unused borrowing capacity on its existing credit facilities as of September&nbsp;30, 2024.
The company returned&nbsp;$591&nbsp;million to shareholders through dividend payments and share repurchases during the nine-months. As of September&nbsp;30, there were 11.9 million shares remaining under the current repurchase authorization.
Martin Marietta CEO&nbsp;Ward Nye said, &#8220;Significant July precipitation together with Tropical Storm Debby in North Carolina, Hurricane Beryl in Texas and Hurricane Helene across much of our Southeast footprint all occurred during the quarter.&#8221;
&#8220;Although these events are short-term and temporary, they nonetheless adversely impacted our&nbsp;third-quarter&nbsp;product shipments, geographic mix and financial results..,&#8221; Nye added.
<a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">2024&nbsp;Guidance Revised</a>: Martin Marietta Materials lowered revenues to&nbsp;$6.450 billion -$6.705 billion (from $6.50 billion &#8211; $6.94 billion)&nbsp;vs. consensus&nbsp;$6.61 billion and adjusted EBITDA to&nbsp;$2.015 billion-$2.115 billion <a target="_blank" href="https://www.benzinga.com//node/40252844" rel="noreferrer noopener">(from&nbsp;$2.10 billion &#8211; $2.30&nbsp;billion prior)</a>.
The company now expects average selling price growth of&nbsp;9.0% &#8211; 11.0% for Aggregates.&nbsp;
Nye added, &#8220;Looking ahead to 2025 and beyond, we expect to benefit from record levels of federal and state investments in highways, streets and bridges. Additionally, reshoring and the build-out of artificial intelligence infrastructure should provide steady growth in these aggregates-intensive end markets for years to come.&#8221;
&#8220;Further, although higher interest rates continue to affect residential construction activity, we are encouraged by recent Federal Reserve policy actions and the likelihood of more interest rate cuts later this year, which should support a recovery in housing and, subsequently, light nonresidential construction activity.&#8221;
&#8220;Importantly, we fully expect our aggregates price/cost spread to continue to expand over time, driving improvement in unit profitability through macroeconomic cycles.&#8221;
Investors can gain exposure to the stock via&nbsp;TCW Transform Supply Chain ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SUPP#NYSE">SUPP</a>) and&nbsp;Invesco Building &amp; Construction ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PKB#NYSE">PKB</a>).
Price Action: MLM shares are up 2.62% at $599.15 at the last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com//node/41624198" target="_blank" rel="noreferrer noopener">GSK&#8217;s Q3 Earnings Hit By Lower Than Expected Vaccine Sales, Cautions Lower Revenue For 2024</a></li>
</ul>

Equities

Movers

PowerShares ETF Trust Dynamic Building &nstruction Portfolio

Comments

CVC Capital Partners

CVC Capital Partners (CVCCF) Opciones

Loading...

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL